With a market capitalization of\u00a0$61.8 billion, Pennsylvania-based Cencora, Inc. (COR) is a\u00a0leading global pharmaceutical services and drug distribution company, formerly known as AmerisourceBergen. It plays a critical role in the healthcare supply chain, acting as an intermediary between drug manufacturers and healthcare providers.<\/p>\n
The company is expected to release its\u00a0Q2 2026\u00a0earnings results on Tuesday, May 6, before the market opens. Ahead of this event, analysts anticipate Cencora to generate\u00a0earnings of $4.81 per share, representing an increase of 8.8% from $4.42 per share reported in the same quarter last year. The company has surpassed the Street\u2019s bottom-line estimates in each of the past four quarters.<\/p>\n
For fiscal 2026, analysts expect the company to report an EPS of $17.57, indicating a 9.8% increase from\u00a0$16 reported in fiscal 2025. Also, its EPS is expected to grow 11.3% year over year to $19.56 in fiscal 2027.<\/p>\n Shares of Cencora have surged\u00a013.3% over the past 52 weeks, underperforming the S&P 500 Index\u2019s ($SPX)\u00a033.5% rise\u00a0but outpacing the State Street Health Care Select Sector SPDR ETF\u2019s (XLV)\u00a07.6% return\u00a0during the same time frame.<\/p>\n On Mar. 23,\u00a0Cencora agreed to acquire EyeSouth Partners\u2019 retina business for $1.1 billion, with the physicians set to join its Retina Consultants of America (RCA) platform. The deal strengthens Cencora\u2019s position in specialty eye care, expanding its network and enhancing access to advanced retina treatments and clinical research. COR\u00a0shares popped 2.1% in the next trading session.<\/p>\n Analysts\u2019 consensus view on COR is highly bullish, with a \u201cStrong Buy\u201d rating overall. Among 13 analysts covering the stock, 11 suggest a \u201cStrong Buy\u201d and two analysts give a \u201cHold.\u201d Its mean price target of $407.92 represents a 26.5% potential upside to current price levels.<\/p>\n On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com <\/i><\/p>\n<\/p><\/div>\n<\/div>\n<\/div>
<\/div>\n<\/div>